Gelonghui, January 15, 丨 Kang Feng Bio-B (06922.HK) issued an announcement. Following approval from the State Drug Administration (“State Drug Administration”) for the cryotherapy equipment supporting the cryoadhesion treatment system on December 22, 2023, other components of the cryoadhesion treatment system (that is, single-use cryoprobes) have obtained approval from the State Drug Administration on January 9, 2024. After obtaining all such approvals from the State Drug Administration, the Group's cryoadhesion treatment system has been approved for marketing by the State Drug Administration.
The cryoadhesion treatment system uses subcritical refrigeration technology and pressure-controlled heat transfer technology for rapid cryoadhesion. It will be used for cryo-removal of foreign matter, mucus, blood clots, and necrotic tissue in the airways, as well as cryo-biopsies of bronchial and lung tissue.